Page 82 - MEMORIA ANUAL 2021
P. 82
MEMORIA ANUAL 2021 SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
PETHEMA
FUNDACIÓN ESPAÑOLA DE HEMATOLOGÍA Y HEMOTERAPIA
Puig N, Paiva B, Contreras T, Cedena MT, Rosiñol L, Martínez J, Oriol A, Blanchard MJ, Ríos, Íñigo, Sureda Balari A, Hernández-García MT, de La Rubia J, Krsnik I, Moraleda JM, Orfao A, Bladé J, San-Miguel JF, Lahuerta JJ, Mateos MV .
• Assessment of treatment response by mass spectrometry in newly diagnosed mul- tiple myeloma patients from the GEM2012MENOS65 clinical trial: comparison with standard SPEP/IFE.
26th Congress of the European-Hematology-Association (EHA). EHA2021 VIRTUAL, Jun 9-17.
Puig N, Contreras T, Paiva B, Cedena MT, Rosiñol L, García Sanz R, Martínez-López J, Oriol A, Blanchard MJ, Ríos R, Martín J, Sureda A, Hernández MT, de la Rubia J, Krsnik I, Mora- leda JM, Palomera L, Íñigo MB, Bargay J, Bladé J, San Miguel J, Lahuerta JJ, Mateos MV .
• Impact of t(11;14) according to induction regimen in newly diagnosed transplant-eli- gible multiple myeloma patients: long term follow-up of GEM05MENOS65 PETHEMA/ GEM study.
26th Congress of the European-Hematology-Association (EHA). EHA2021 VIRTUAL, Jun 9-17.
Moreno DF, Oriol A, Teruel AI, López de la Guía A, Blanchard MJ, de la Rubia J, Granell M, Sampol A, Palomera L, González Y, Bengoechea E, Íñigo B, Hernández MT, de Arriba F, Gutiérrez NC, Martín-Ramos ML, Mateos MV, Martínez-López J, Alegre A, Lahuerta JJ, San Miguel J, Bladé J, Rosiñol L .
• Severity of COVID-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic.
63rd Annual Meeting of the American-Society-of-Hematology (ASH). Georgia, Dec 11-14, 2021. Martínez-López J, Mateos MV, López-Muñoz N, Senin Magan MA, De Miguel MD, López de la Guía A, Sureda A, Encinas C, Conde Royo D, Rosiñol L, García Tomás L, Hernández- Rivas JA, Rojas JA, Alegre A, Blanchard MJ, Escalante Barrigón F, González García E, Íñigo B, Bravo Barahona P, Peñalver FJ, De La Rubia J, Fernández-Escalada N, Alonso Alonso JM, Bladé J, Lahuerta JJ, De La Cruz J, San-Miguel JF .
• Selinexor in Combination with Daratumumab-Bortezomib and Dexamethasone for the Treatment of Relapse or Refractory Multiple Myeloma: Initial Results of the Phase 2, Open-Label, Multicenter GEM-Selibordara Study.
63rd Annual Meeting of the American-Society-of-Hematology (ASH). Georgia, Dec 11-14, 2021. Rodríguez-Otero P, González De La Calle V, Sureda A, De Arriba F, Reinoso Segura M, Ribas P, González AP, González-Montes Y, Oriol A, Martínez-López J, González MS, Her- nández MT, Sirvent M, Bladé Creixenti J, Lahuerta JJ, San-Miguel JF, Mateos MV .
82